How to Profit From Every Biotech Buyout

Amgen's acquisition of Onyx underscores the fact that one simple biotech investment may also be the best one. More 

Offshore Field of Dreams: Israel’s ‘Gassy’ Opportunity

Investors usually associate Israel with its technology, but recent developments in offshore drilling could make energy a big part of the country's future. More 

Teva Pharmaceuticals a Dodgy Dividend Choice

Teva develops, manufactures,and distributes pharmaceutical products worldwide. This dividend achiever is a solid payer, but not a buy for our portfolio. More 

Drug Companies Reach $2.15B Settlement in Acid Reflux Battle

Two generic drug makers will pay Pfizer and Takeda Pharmaceutical $2.15 billion for producing generic versions of a heartburn drug before its patent expired. More 

How To Profit From The Next Wave Of Dividends

In this low interest rate environment, dividends are still looking great, and here are over 50 companies going ex-dividend over the next week to review More 

OPKO Health’s Healthy Buyout Binge

This healthcare name is rapidly building up a business worth watching. And the possibility of OPKO itself getting bought out isn't too remote. More 

9 Pharmaceutical Stocks to Sell Now

This week, the overall grades of nine Pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More